查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1971915

非小細胞肺癌 (NSCLC) 市場分析及預測（至 2035 年）：按類型、產品類型、技術、應用、最終用戶、疾病分期、設備、解決方案和流程分類

Non-Small Cell Lung Cancer (NSCLC) Market Analysis and Forecast to 2035: Type, Product, Technology, Application, End User, Stage, Device, Solutions, Process
出版日期: | 出版商: Global Insight Services | 英文 385 Pages | 商品交期: 3-5個工作天內

價格
簡介目錄

非小細胞肺癌 (NSCLC) 市場預計將從 2024 年的 195 億美元成長到 2034 年的 616 億美元，複合年成長率約為 12.2%。 NSCLC 市場涵蓋了 NSCLC（最常見的肺癌類型）治療方案的研發、生產和分銷。該市場以創新治療方法，例如標靶治療和免疫療法，旨在改善患者預後。在發病率上升和精準醫療進步的推動下，由於對研究和臨床試驗的大量投資，該市場正穩步成長。主要趨勢包括個人化醫療方法、聯合治療以及整合生物標記以提高治療效果。

非小細胞肺癌 (NSCLC) 市場正經歷強勁成長，主要得益於標靶治療和免疫療法的進步。目前，標靶治療領域表現最佳，主導EGFR 抑制劑和 ALK 抑制劑因其對特定基因突變的療效而備受青睞。免疫療法，尤其是 PD-1 和 PD-L1 抑制劑，是表現第二好的領域，反映出它們作為第一線治療方案的應用日益廣泛。聯合治療發展勢頭強勁，顯著提高了療效並改善了患者預後。儘管化療領域呈下降趨勢，但仍佔據重要地位，尤其是與其他治療方法合併使用時。個人化醫療正成為一項關鍵趨勢，其驅動力來自基因組分析和生物標記識別技術的進步。這一趨勢正在推動伴隨診斷領域的創新和投資。此外，由於患者偏好和成本效益的考慮，市場正朝著門診治療模式轉變。持續的研發投入可望創造新的治療選擇，進一步推動市場成長。

市場區隔
類型 腺癌、鱗狀細胞癌、大細胞癌
產品 標靶治療、免疫療法、化療和放射線治療
科技 生物標記檢測、基因檢測、診斷影像技術、奈米技術
適應症 第一線治療、第二線治療、維持治療、輔助性治療、新輔助輔助性治療
最終用戶 醫院、癌症研究機構、專科診所、製藥公司
階段 第一階段、第二階段、第三階段、第四階段
醫療設備 切片檢查設備、診斷影像系統、放射治療設備
解決方案 病患管理、臨床試驗和藥物研發
過程 藥物發現、臨床開發、監管核准和商業化

市場概況：

非小細胞肺癌 (NSCLC) 市場正經歷動態變化，創新定價策略和新型療法的推出導致市場佔有率顯著波動。新型療法的出現滿足了未被滿足的醫療需求，並改善了患者的治療效果，從而塑造了市場特徵。新進業者的競爭性定價正在重塑市場結構，並促進更廣泛的醫療服務取得和應用。主要地區的定價趨勢各不相同，受到當地法規結構和醫療政策的影響。隨著製藥公司繼續專注於研發以保持其競爭優勢，市場有望進一步發展。就競爭基準而言，NSCLC 市場的特點是老牌製藥巨頭和新興生技公司之間的激烈競爭。監管的影響至關重要，嚴格的核准流程影響新產品上市的速度。北美和歐洲在主導領域處於領先地位，制定了高標準的安全性和有效性要求。儘管這些地區保持著市場佔有率的主導地位，但由於醫療基礎設施投資的增加和患者群體的不斷擴大，亞太地區正在崛起成為關鍵參與者。競爭格局進一步受到策略聯盟和併購的影響，隨著公司尋求加強市場地位和擴大產品系列，這些聯盟和併購變得越來越普遍。

主要趨勢和促進因素：

在標靶治療和免疫療法的推動下，非小細胞肺癌 (NSCLC) 市場正經歷變革性成長。關鍵趨勢包括：開發個人化醫療方法以提高治療效果和患者預後；人工智慧在診斷中的應用加速了早期檢測和精準治療方案的製定，從而推動了市場擴張；生物標記驅動療法的興起是另一項關鍵趨勢，它能夠實現更加個性化和有效的治療方法；研發投入的增加正在刺激創新並創造新的治療選擇；NSCLC發病率的不斷上升以及人口老化顯著推動了對先進治療方案的需求；此外，監管機構的支持和突破性治療方法的快速核准流程也促進了其加速進入市場。新興市場擁有眾多機遇，這些市場的醫療基礎設施正在發展，人們對肺癌的認知也不斷提高。專注於策略合作和拓展產品平臺的公司將更有利於掌握這個充滿活力的市場環境。

限制與挑戰：

非小細胞肺癌（NSCLC）市場面臨許多重大限制與挑戰。其中一個主要挑戰是標靶治療和免疫療法的高成本，限制了低收入地區患者的治療機會。這些先進療法的價格往往高得令人望而卻步，阻礙了其廣泛應用，並加劇了醫療保健資源分配不均的現狀。此外，NSCLC複雜的遺傳背景要求採取個人化治療方案，使得治療通訊協定的標準化變得困難。這種複雜性也增加了醫療服務提供者了解最新進展並據此調整治療方案的負擔。另一個挑戰是新治療方法核准中存在的監管障礙，這可能會延遲產品上市並增加研發成本。此外，NSCLC治療的副作用可能嚴重，影響患者的生活品質和治療順從性。最後，某些地區全面基因組檢測的匱乏阻礙了精準醫療的有效實施，並限制了最佳治療效果的實現。

目錄

第1章執行摘要

第2章 市場亮點

第3章 市場動態

  • 宏觀經濟分析
  • 市場趨勢
  • 市場促進因素
  • 市場機遇
  • 市場限制
  • 複合年均成長率：成長分析
  • 影響分析
  • 新興市場
  • 技術藍圖
  • 戰略框架

第4章 細分市場分析

  • 市場規模及預測：依類型
    • 腺癌
    • 鱗狀細胞癌
    • 大細胞癌
  • 市場規模及預測：依產品分類
    • 標靶治療藥物
    • 免疫療法
    • 化療藥物
    • 放射治療
  • 市場規模及預測：依技術分類
    • 生物標記檢測
    • 基因檢測
    • 診斷影像技術
    • 奈米科技
  • 市場規模及預測：依應用領域分類
    • 一線治療
    • 二級治療
    • 維持治療
    • 輔助性治療
    • 新輔助輔助性治療
  • 市場規模及預測：依最終用戶分類
    • 醫院
    • 癌症研究所
    • 專科診所
    • 製藥公司
  • 市場規模及預測：依疾病階段分類
    • 第一階段
    • 第二階段
    • 第三階段
    • 第四階段
  • 市場規模及預測：依設備分類
    • 切片檢查裝置
    • 診斷影像系統
    • 放射治療設備
  • 市場規模及預測：按解決方案分類
    • 病患管理
    • 臨床試驗
    • 藥物研發
  • 市場規模及預測：依製程分類
    • 藥物發現
    • 臨床開發
    • 監管部門核准
    • 商業化

第5章 區域分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲地區
  • 亞太地區
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲
    • 台灣
    • 亞太其他地區
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 義大利
    • 其他歐洲地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非
    • 撒哈拉以南非洲
    • 其他中東和非洲地區

第6章 市場策略

  • 需求與供給差距分析
  • 貿易和物流限制
  • 價格、成本和利潤率趨勢
  • 市場滲透率
  • 消費者分析
  • 法規概述

第7章 競爭訊息

  • 市場定位
  • 市場占有率
  • 競爭基準
  • 主要企業的策略

第8章：公司簡介

  • BeiGene
  • Innovent Biologics
  • Zai Lab
  • Hutchmed
  • Array BioPharma
  • Blueprint Medicines
  • Mirati Therapeutics
  • Turning Point Therapeutics
  • Iovance Biotherapeutics
  • MacroGenics
  • Daiichi Sankyo
  • Eisai
  • Sumitomo Dainippon Pharma
  • Chugai Pharmaceutical
  • Kyowa Kirin

第9章：關於我們

簡介目錄
Product Code: GIS34093

Non-Small Cell Lung Cancer (NSCLC) Market is anticipated to expand from $19.5 billion in 2024 to $61.6 billion by 2034, growing at a CAGR of approximately 12.2%. The Non-Small Cell Lung Cancer (NSCLC) Market encompasses the development, production, and distribution of therapeutic solutions targeting NSCLC, the most prevalent form of lung cancer. This market is characterized by innovative treatments, including targeted therapies and immunotherapies, aimed at improving patient outcomes. Driven by rising incidence rates and advancements in precision medicine, the market is poised for growth, with significant investment in research and clinical trials. Key trends include personalized medicine approaches, combination therapies, and the integration of biomarkers for enhanced treatment efficacy.

The Non-Small Cell Lung Cancer (NSCLC) Market is experiencing robust growth, primarily driven by advancements in targeted therapies and immunotherapies. The targeted therapy segment is currently the top-performing, with EGFR inhibitors and ALK inhibitors leading due to their efficacy in specific genetic mutations. Immunotherapy, particularly PD-1 and PD-L1 inhibitors, is the second highest-performing segment, reflecting its increasing adoption as a first-line treatment. Combination therapies are gaining momentum, offering enhanced efficacy and improved patient outcomes. The chemotherapy segment, while declining, remains relevant, especially in combination with other modalities. Personalized medicine is emerging as a key trend, supported by advancements in genomic profiling and biomarker identification. This trend is driving innovation and investment in companion diagnostics. The market is also witnessing a shift towards outpatient settings, influenced by patient preference and cost efficiency. Continuous research and development efforts are expected to yield novel treatment options, further propelling market growth.

Market Segmentation
TypeAdenocarcinoma, Squamous Cell Carcinoma, Large Cell Carcinoma
ProductTargeted Therapy Drugs, Immunotherapy Drugs, Chemotherapy Drugs, Radiotherapy
TechnologyBiomarker Testing, Genetic Testing, Imaging Technologies, Nanotechnology
ApplicationFirst-Line Treatment, Second-Line Treatment, Maintenance Therapy, Adjuvant Therapy, Neoadjuvant Therapy
End UserHospitals, Cancer Research Institutes, Specialty Clinics, Pharmaceutical Companies
StageStage I, Stage II, Stage III, Stage IV
DeviceBiopsy Devices, Diagnostic Imaging Systems, Radiotherapy Equipment
SolutionsPatient Management, Clinical Trials, Drug Development
ProcessDrug Discovery, Clinical Development, Regulatory Approval, Commercialization

Market Snapshot:

The Non-Small Cell Lung Cancer (NSCLC) market is witnessing dynamic changes, with significant shifts in market share driven by innovative pricing strategies and the introduction of new therapeutic products. The landscape is characterized by the launch of novel treatments that aim to address unmet medical needs, thereby enhancing patient outcomes. The competitive pricing of these new entrants is reshaping the market dynamics, encouraging broader accessibility and adoption. Key regions are experiencing varied pricing trends, influenced by local regulatory frameworks and healthcare policies. The market is poised for further evolution as pharmaceutical companies continue to focus on research and development to maintain a competitive edge. In terms of competition benchmarking, the NSCLC market is marked by intense rivalry among established pharmaceutical giants and emerging biotech firms. Regulatory influences play a pivotal role, with stringent approval processes impacting the pace of new product introductions. North America and Europe dominate the regulatory landscape, setting high standards for safety and efficacy. These regions also lead in terms of market share, yet Asia-Pacific is emerging as a significant player due to increased investment in healthcare infrastructure and a growing patient population. The competitive landscape is further shaped by strategic alliances and mergers, which are becoming increasingly common as companies seek to enhance their market position and expand their product portfolios.

Geographical Overview:

The NSCLC market is witnessing robust growth across diverse regions, each exhibiting unique characteristics. North America remains a dominant force, driven by advanced healthcare infrastructure and significant R&D investments. The region's focus on innovative therapies and precision medicine is fostering market expansion. Europe follows closely, with strong governmental support and a rising prevalence of lung cancer contributing to market dynamics. The Asia Pacific region is experiencing rapid growth, propelled by increased healthcare spending and a burgeoning population. Countries like China and India are emerging as key players, with large patient pools and improving healthcare access. Latin America and the Middle East & Africa are also showing promising growth, albeit at a slower pace. In Latin America, Brazil and Mexico are leading the charge with enhanced healthcare initiatives. The Middle East & Africa are recognizing the need for improved cancer care, spurring investments in healthcare infrastructure and treatment options.

Key Trends and Drivers:

The Non-Small Cell Lung Cancer (NSCLC) market is experiencing transformative growth driven by advancements in targeted therapies and immunotherapies. Key trends include the development of personalized medicine approaches, enhancing treatment efficacy and patient outcomes. The integration of artificial intelligence in diagnostics is accelerating early detection and precision treatment planning, boosting market expansion. The rise of biomarker-driven therapies is another pivotal trend, allowing for more tailored and effective treatment regimens. Increasing investment in research and development is fostering innovation, leading to novel therapeutic options. The growing prevalence of NSCLC, coupled with an aging population, is significantly driving demand for advanced treatment solutions. Moreover, regulatory support and expedited approval processes for breakthrough therapies are facilitating faster market entry. Opportunities abound in emerging markets where healthcare infrastructure is improving, and awareness of lung cancer is rising. Companies focusing on strategic collaborations and expanding their product pipelines are well-positioned to capitalize on these dynamic market conditions.

Restraints and Challenges:

The NSCLC market encounters several significant restraints and challenges. One primary challenge is the high cost of targeted therapies and immunotherapies, which limits access for patients in low-income regions. These advanced treatments often come with prohibitive pricing, deterring widespread adoption and exacerbating healthcare inequalities. Moreover, the complexity of NSCLC's genetic landscape necessitates personalized treatment approaches, complicating the standardization of care protocols. This complexity also increases the burden on healthcare providers to stay updated with the latest developments and tailor treatments accordingly. Another challenge is the regulatory hurdles associated with the approval of new therapies, which can delay market entry and increase development costs. Additionally, the side effects associated with NSCLC treatments can be severe, impacting patient quality of life and adherence to therapy. Finally, the limited availability of comprehensive genomic testing in certain regions hampers the ability to implement precision medicine effectively, constraining optimal treatment outcomes.

Key Players:

BeiGene, Innovent Biologics, Zai Lab, Hutchmed, Array BioPharma, Blueprint Medicines, Mirati Therapeutics, Turning Point Therapeutics, Iovance Biotherapeutics, MacroGenics, Daiichi Sankyo, Eisai, Sumitomo Dainippon Pharma, Chugai Pharmaceutical, Kyowa Kirin

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Technology
  • 2.4 Key Market Highlights by Application
  • 2.5 Key Market Highlights by End User
  • 2.6 Key Market Highlights by Stage
  • 2.7 Key Market Highlights by Device
  • 2.8 Key Market Highlights by Solutions
  • 2.9 Key Market Highlights by Process

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Adenocarcinoma
    • 4.1.2 Squamous Cell Carcinoma
    • 4.1.3 Large Cell Carcinoma
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Targeted Therapy Drugs
    • 4.2.2 Immunotherapy Drugs
    • 4.2.3 Chemotherapy Drugs
    • 4.2.4 Radiotherapy
  • 4.3 Market Size & Forecast by Technology (2020-2035)
    • 4.3.1 Biomarker Testing
    • 4.3.2 Genetic Testing
    • 4.3.3 Imaging Technologies
    • 4.3.4 Nanotechnology
  • 4.4 Market Size & Forecast by Application (2020-2035)
    • 4.4.1 First-Line Treatment
    • 4.4.2 Second-Line Treatment
    • 4.4.3 Maintenance Therapy
    • 4.4.4 Adjuvant Therapy
    • 4.4.5 Neoadjuvant Therapy
  • 4.5 Market Size & Forecast by End User (2020-2035)
    • 4.5.1 Hospitals
    • 4.5.2 Cancer Research Institutes
    • 4.5.3 Specialty Clinics
    • 4.5.4 Pharmaceutical Companies
  • 4.6 Market Size & Forecast by Stage (2020-2035)
    • 4.6.1 Stage I
    • 4.6.2 Stage II
    • 4.6.3 Stage III
    • 4.6.4 Stage IV
  • 4.7 Market Size & Forecast by Device (2020-2035)
    • 4.7.1 Biopsy Devices
    • 4.7.2 Diagnostic Imaging Systems
    • 4.7.3 Radiotherapy Equipment
  • 4.8 Market Size & Forecast by Solutions (2020-2035)
    • 4.8.1 Patient Management
    • 4.8.2 Clinical Trials
    • 4.8.3 Drug Development
  • 4.9 Market Size & Forecast by Process (2020-2035)
    • 4.9.1 Drug Discovery
    • 4.9.2 Clinical Development
    • 4.9.3 Regulatory Approval
    • 4.9.4 Commercialization

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Technology
      • 5.2.1.4 Application
      • 5.2.1.5 End User
      • 5.2.1.6 Stage
      • 5.2.1.7 Device
      • 5.2.1.8 Solutions
      • 5.2.1.9 Process
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Technology
      • 5.2.2.4 Application
      • 5.2.2.5 End User
      • 5.2.2.6 Stage
      • 5.2.2.7 Device
      • 5.2.2.8 Solutions
      • 5.2.2.9 Process
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Technology
      • 5.2.3.4 Application
      • 5.2.3.5 End User
      • 5.2.3.6 Stage
      • 5.2.3.7 Device
      • 5.2.3.8 Solutions
      • 5.2.3.9 Process
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Technology
      • 5.3.1.4 Application
      • 5.3.1.5 End User
      • 5.3.1.6 Stage
      • 5.3.1.7 Device
      • 5.3.1.8 Solutions
      • 5.3.1.9 Process
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Technology
      • 5.3.2.4 Application
      • 5.3.2.5 End User
      • 5.3.2.6 Stage
      • 5.3.2.7 Device
      • 5.3.2.8 Solutions
      • 5.3.2.9 Process
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Technology
      • 5.3.3.4 Application
      • 5.3.3.5 End User
      • 5.3.3.6 Stage
      • 5.3.3.7 Device
      • 5.3.3.8 Solutions
      • 5.3.3.9 Process
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Technology
      • 5.4.1.4 Application
      • 5.4.1.5 End User
      • 5.4.1.6 Stage
      • 5.4.1.7 Device
      • 5.4.1.8 Solutions
      • 5.4.1.9 Process
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Technology
      • 5.4.2.4 Application
      • 5.4.2.5 End User
      • 5.4.2.6 Stage
      • 5.4.2.7 Device
      • 5.4.2.8 Solutions
      • 5.4.2.9 Process
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Technology
      • 5.4.3.4 Application
      • 5.4.3.5 End User
      • 5.4.3.6 Stage
      • 5.4.3.7 Device
      • 5.4.3.8 Solutions
      • 5.4.3.9 Process
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Technology
      • 5.4.4.4 Application
      • 5.4.4.5 End User
      • 5.4.4.6 Stage
      • 5.4.4.7 Device
      • 5.4.4.8 Solutions
      • 5.4.4.9 Process
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Technology
      • 5.4.5.4 Application
      • 5.4.5.5 End User
      • 5.4.5.6 Stage
      • 5.4.5.7 Device
      • 5.4.5.8 Solutions
      • 5.4.5.9 Process
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Technology
      • 5.4.6.4 Application
      • 5.4.6.5 End User
      • 5.4.6.6 Stage
      • 5.4.6.7 Device
      • 5.4.6.8 Solutions
      • 5.4.6.9 Process
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Technology
      • 5.4.7.4 Application
      • 5.4.7.5 End User
      • 5.4.7.6 Stage
      • 5.4.7.7 Device
      • 5.4.7.8 Solutions
      • 5.4.7.9 Process
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Technology
      • 5.5.1.4 Application
      • 5.5.1.5 End User
      • 5.5.1.6 Stage
      • 5.5.1.7 Device
      • 5.5.1.8 Solutions
      • 5.5.1.9 Process
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Technology
      • 5.5.2.4 Application
      • 5.5.2.5 End User
      • 5.5.2.6 Stage
      • 5.5.2.7 Device
      • 5.5.2.8 Solutions
      • 5.5.2.9 Process
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Technology
      • 5.5.3.4 Application
      • 5.5.3.5 End User
      • 5.5.3.6 Stage
      • 5.5.3.7 Device
      • 5.5.3.8 Solutions
      • 5.5.3.9 Process
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Technology
      • 5.5.4.4 Application
      • 5.5.4.5 End User
      • 5.5.4.6 Stage
      • 5.5.4.7 Device
      • 5.5.4.8 Solutions
      • 5.5.4.9 Process
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Technology
      • 5.5.5.4 Application
      • 5.5.5.5 End User
      • 5.5.5.6 Stage
      • 5.5.5.7 Device
      • 5.5.5.8 Solutions
      • 5.5.5.9 Process
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Technology
      • 5.5.6.4 Application
      • 5.5.6.5 End User
      • 5.5.6.6 Stage
      • 5.5.6.7 Device
      • 5.5.6.8 Solutions
      • 5.5.6.9 Process
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Technology
      • 5.6.1.4 Application
      • 5.6.1.5 End User
      • 5.6.1.6 Stage
      • 5.6.1.7 Device
      • 5.6.1.8 Solutions
      • 5.6.1.9 Process
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Technology
      • 5.6.2.4 Application
      • 5.6.2.5 End User
      • 5.6.2.6 Stage
      • 5.6.2.7 Device
      • 5.6.2.8 Solutions
      • 5.6.2.9 Process
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Technology
      • 5.6.3.4 Application
      • 5.6.3.5 End User
      • 5.6.3.6 Stage
      • 5.6.3.7 Device
      • 5.6.3.8 Solutions
      • 5.6.3.9 Process
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Technology
      • 5.6.4.4 Application
      • 5.6.4.5 End User
      • 5.6.4.6 Stage
      • 5.6.4.7 Device
      • 5.6.4.8 Solutions
      • 5.6.4.9 Process
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Technology
      • 5.6.5.4 Application
      • 5.6.5.5 End User
      • 5.6.5.6 Stage
      • 5.6.5.7 Device
      • 5.6.5.8 Solutions
      • 5.6.5.9 Process

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 BeiGene
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Innovent Biologics
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Zai Lab
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Hutchmed
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Array BioPharma
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Blueprint Medicines
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Mirati Therapeutics
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Turning Point Therapeutics
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Iovance Biotherapeutics
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 MacroGenics
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Daiichi Sankyo
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Eisai
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Sumitomo Dainippon Pharma
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Chugai Pharmaceutical
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Kyowa Kirin
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us